Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Regulus Therapeutics appoints R&D officer

Wednesday, October 5, 2016 13:53
% of readers think this story is Fact. Add your two cents.

Biopharmaceutical company Regulus Therapeutics Inc (NASDAQ:RGLS) has announced the appointment of Timothy Wright, MD, as chief research & development officer.

The company, which specialises in the discovery and development of innovative medicines targeting microRNAs (ribonucleic acida), said Dr Wright would report to Paul Grint, MD, president and chief executive officer of Regulus.

Dr. Wright will oversee Regulus’s research, drug discovery, clinical development, and regulatory affairs functions.

“Tim brings over 30 years of academic and industry experience that includes leading worldwide clinical development programs,” said Grint.

“His expertise in translational research will enable us to significantly advance and develop our pipeline. With three clinical-stage compounds, a fourth clinical candidate to be nominated by year-end, and multiple promising compounds in our pipeline, Tim joins us at an exciting time in the evolution of the company.”

Shares in Regulus rose 8.6% to US$3.52 on the news.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.